CA2968399A1 - Anti-mutated kras t cell receptors - Google Patents

Anti-mutated kras t cell receptors Download PDF

Info

Publication number
CA2968399A1
CA2968399A1 CA2968399A CA2968399A CA2968399A1 CA 2968399 A1 CA2968399 A1 CA 2968399A1 CA 2968399 A CA2968399 A CA 2968399A CA 2968399 A CA2968399 A CA 2968399A CA 2968399 A1 CA2968399 A1 CA 2968399A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
chain
acid sequence
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2968399A
Other languages
English (en)
French (fr)
Inventor
Qiong J. Wang
Zhiya Yu
James C. Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA2968399A1 publication Critical patent/CA2968399A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
CA2968399A 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors Pending CA2968399A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462084654P 2014-11-26 2014-11-26
US62/084,654 2014-11-26
US201562171321P 2015-06-05 2015-06-05
US62/171,321 2015-06-05
PCT/US2015/062269 WO2016085904A1 (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Publications (1)

Publication Number Publication Date
CA2968399A1 true CA2968399A1 (en) 2016-06-02

Family

ID=54838442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2968399A Pending CA2968399A1 (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Country Status (17)

Country Link
US (3) US11207394B2 (OSRAM)
EP (3) EP3666288B1 (OSRAM)
JP (2) JP6863893B2 (OSRAM)
KR (1) KR102622784B1 (OSRAM)
CN (3) CN113956349B (OSRAM)
AU (3) AU2015353720B2 (OSRAM)
CA (1) CA2968399A1 (OSRAM)
ES (2) ES2784261T3 (OSRAM)
HU (1) HUE065689T2 (OSRAM)
IL (1) IL252258B (OSRAM)
MX (1) MX384919B (OSRAM)
PL (1) PL3223850T3 (OSRAM)
PT (1) PT3223850T (OSRAM)
SA (1) SA517381608B1 (OSRAM)
SG (2) SG10201913978RA (OSRAM)
SI (1) SI3223850T1 (OSRAM)
WO (1) WO2016085904A1 (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968399A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors
MX2018003062A (es) 2015-09-15 2018-09-11 Us Health Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
IL264425B2 (en) * 2016-08-02 2023-09-01 Us Secretary Department Of Health And Human Services t cell receptors against kras-g20
WO2018069871A2 (en) * 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
JP7250677B2 (ja) 2016-12-22 2023-04-03 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
SG11201909751TA (en) * 2017-05-12 2019-11-28 Augusta University Research Institute Inc Human alpha fetoprotein-specific t cell receptors and uses thereof
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
CR20240019A (es) * 2017-09-20 2024-02-15 Us Health RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150)
IL273516B2 (en) * 2017-09-29 2025-06-01 Us Health Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
EP4269595A3 (en) 2017-10-05 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods for selectively expanding cells expressing a tcr with a murine constant region
JP7385566B2 (ja) 2017-12-04 2023-11-22 アメリカ合衆国 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
CN110016074B (zh) * 2018-01-08 2021-03-30 中国科学院广州生物医药与健康研究院 Mage-a3人源化t细胞受体
MX2020014243A (es) * 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
CA3109232A1 (en) 2018-08-16 2020-02-20 Biontech Us Inc. T cell receptor constructs and uses thereof
US12448428B2 (en) 2019-01-22 2025-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted t cell receptors against RAS with G12R mutation
SG11202108039QA (en) * 2019-01-25 2021-08-30 Univ Pennsylvania Compositions and methods for targeting mutant ras
WO2020172332A1 (en) * 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
WO2020210202A1 (en) * 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
AU2020285380A1 (en) * 2019-05-27 2022-01-20 Provincial Health Services Authority Immunotherapy constructs targeting KRAS antigens
AU2020282369A1 (en) 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses
AU2020289484A1 (en) * 2019-06-07 2021-12-23 Emory University KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
EP3997131A4 (en) 2019-07-12 2023-08-02 The Regents of the University of California Chemically controlled monoclonal antibody target engagement
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
US12453774B2 (en) 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
KR20220098379A (ko) * 2019-11-15 2022-07-12 그릿스톤 바이오, 인코포레이티드 공유 네오항원을 표적으로 하는 항원-결합 단백질
IL295252A (en) * 2020-02-12 2022-10-01 Us Health Human leukocyte antigen type i-restricted t-cell receptors against ras with the g12d mutation
MX2022009825A (es) * 2020-02-14 2022-10-13 Us Health Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
US20230181714A1 (en) * 2020-05-27 2023-06-15 Vanderbilt University Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
US20230257440A1 (en) * 2020-07-16 2023-08-17 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted drb t cell receptors against ras with g12v mutation
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
US20240000834A1 (en) * 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
US20240175047A1 (en) 2021-02-25 2024-05-30 Alaunos Therapeutics, Inc. Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
CN116981470A (zh) * 2021-03-19 2023-10-31 Cue生物制药股份有限公司 T细胞调节多肽和其使用方法
CN116063511B (zh) * 2021-09-30 2023-10-03 北京可瑞生物科技有限公司 抗原结合蛋白及其应用
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
EP4466283A1 (en) 2022-01-21 2024-11-27 T-Knife GmbH Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114591443A (zh) * 2022-03-07 2022-06-07 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于scTv的嵌合受体CSR及其应用
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用
CN114835800B (zh) * 2022-05-27 2023-10-13 重庆医科大学 Tcr或其抗原结合片段及其应用
EP4584298A1 (en) * 2022-09-08 2025-07-16 The Regents Of The University Of California Binding agent recognition of drug-peptide conjugates
WO2024147556A1 (ko) * 2023-01-05 2024-07-11 의료법인 명지의료재단 K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물
EP4660201A1 (en) * 2023-01-13 2025-12-10 Corregene Biotechnology Co., Ltd. Antigen binding protein and use thereof
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
CN118909132A (zh) * 2023-05-06 2024-11-08 北京鼎成肽源生物技术有限公司 靶向kras g12v突变的tcr分子和细胞及其应用
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
CN117143823B (zh) * 2023-09-11 2024-07-16 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C
WO2025056656A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709002B1 (en) * 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
PT2016102E (pt) * 2006-05-03 2012-05-15 Us Gov Health & Human Serv Recetores de célula t quimérica e materiais relacionados e métodos de uso
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
CN102712953A (zh) * 2009-09-17 2012-10-03 密歇根大学董事会 前列腺癌中的复发性基因融合物
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CN104131034B (zh) * 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
CA2968399A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors
CN105802909B (zh) * 2014-12-31 2021-01-01 中国医学科学院基础医学研究所 具有her2特异性tcr的t细胞制备物及其用途
CN108395479B (zh) 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
CN113621070A (zh) * 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用

Also Published As

Publication number Publication date
AU2015353720A1 (en) 2017-06-08
JP7297807B2 (ja) 2023-06-26
CN107223134B (zh) 2021-11-16
AU2020203465B2 (en) 2022-11-17
MX384919B (es) 2025-03-14
JP2021104044A (ja) 2021-07-26
PL3223850T3 (pl) 2020-08-24
KR102622784B1 (ko) 2024-01-09
ES2784261T3 (es) 2020-09-23
HK1243642A1 (en) 2018-07-20
HUE065689T2 (hu) 2024-06-28
CN107223134A (zh) 2017-09-29
EP4286407A3 (en) 2024-03-06
EP4286407A2 (en) 2023-12-06
IL252258B (en) 2021-12-01
US11207394B2 (en) 2021-12-28
SA517381608B1 (ar) 2021-03-11
EP3666288A1 (en) 2020-06-17
NZ732045A (en) 2024-04-26
AU2015353720B2 (en) 2020-02-27
US20170304421A1 (en) 2017-10-26
ES2965689T3 (es) 2024-04-16
US20220088164A1 (en) 2022-03-24
EP3223850A1 (en) 2017-10-04
KR20170099905A (ko) 2017-09-01
MX2017006865A (es) 2018-01-11
SG10201913978RA (en) 2020-03-30
AU2020203465A1 (en) 2020-06-18
JP6863893B2 (ja) 2021-04-21
CN113956349A (zh) 2022-01-21
US20250263462A1 (en) 2025-08-21
CN118994363A (zh) 2024-11-22
WO2016085904A1 (en) 2016-06-02
IL252258A0 (en) 2017-07-31
JP2017536825A (ja) 2017-12-14
AU2023200614A1 (en) 2023-03-09
US12312391B2 (en) 2025-05-27
EP3223850B1 (en) 2020-01-08
CN113956349B (zh) 2024-09-06
EP3666288B1 (en) 2023-09-27
SI3223850T1 (sl) 2020-09-30
PT3223850T (pt) 2020-04-13
SG11201704155UA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
US12312391B2 (en) Anti-mutated KRAS T cell receptors
US12187779B2 (en) Anti-human papillomavirus 16 E6 T cell receptors
CA2950192A1 (en) Anti-human papillomavirus 16 e7 t cell receptors
HK40031837A (en) Anti-mutated kras t cell receptors
HK40031837B (en) Anti-mutated kras t cell receptors
HK40065450A (en) Anti-mutated kras t cell receptors
HK40065450B (zh) 抗突变的kras的t细胞受体
HK40018191A (en) Anti-human papillomavirus 16 e6 t cell receptors
HK1243642B (en) Anti-mutated kras t cell receptors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201117

EEER Examination request

Effective date: 20201117

EEER Examination request

Effective date: 20201117

EEER Examination request

Effective date: 20201117

EEER Examination request

Effective date: 20201117

EEER Examination request

Effective date: 20201117

EEER Examination request

Effective date: 20201117